Biosion monoclonal antibody therapies to be featured at the American Association for Cancer Research (AACR) meeting 2022

Biosion, Inc. (“Biosion”), a global R&D stage biotechnology company, announced today the upcoming presentations of non-clinical data from its oncology pipeline, including BSI-060T:  anti-siglec-15 antibody and BSI-082: anti-SIRP antibody, at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 8 to 13, 2022.

BSI-060T,a High Affinity, Fully Human Anti-Siglec-15 Antibody as an Alternative Immune Checkpoint Blocker

BSI-060T is a fully human IgG1κ monoclonal antibody, discovered through Biosion’s H³ antibody discovery platform, is able to bind to Siglec-15 protein with high affinity and to potently neutralize Siglec-15-medicated inhibition of CD3-induced T-cell proliferation. BSI-060T exhibits best-in-class biophysical properties and functional characteristics, supporting the initiation of development activities for multiple indications including non-small lung cancer and breast cancer.

Learn more

https://www.abstractsonline.com/pp8/#!/10517/presentation/17741

BSI-082, a Fully Human Anti-SIRPα Antibody with Both High Specificity and Broad Coverage of SIRPα Variant Populations

BSI-082 is a fully human IgG1/k mAb that binds to SIRPα and blocks the SIRPα/CD47-mediated signaling pathway discovered through Biosion’s H³ antibody discovery platform. BSI-082 exhibits best-in-class biophysical properties, SIRPα specificity, broad SIRPα variant binding and superior functional characteristics, supporting the initiation of development activities for a variety of cancer types.  

Learn more

https://www.abstractsonline.com/pp8/#!/10517/presentation/18074

About AACR Annual Meeting 

The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

About Biosion, Inc. 

Biosion is a global R&D biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived technologies including the H³ antibody discovery, SynTracer™ HT-endocytosis and Flexibody™ bispecific platforms. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in phase 1 clinical trials for atopic dermatitis and severe asthma. Biosion and partners have plans to progress additional assets into the clinic for oncology indications over the next year. Biosion has operations in the US, Australia, and China. To learn more about Biosion visit www.biosion.com.

Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology

  • Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106), a fully human anti-Siglec-15 monoclonal antibody
  • Biosion earns a $10 million upfront license fee; additional milestone payments and royalties on commercial sales to be earned upon advancement of PYX-106

Newark, DE, U.S. and Nanjing, China – March 29, 2022.  Biosion, Inc., a global R&D stage biotechnology company, today announced that Biosion and Pyxis Oncology (NASDAQ: PYXS) have entered into an agreement under which Pyxis Oncology will be granted an exclusive license to develop and commercialize Biosion’s anti-Siglec-15 monoclonal antibody, BSI-060T (now referred to as PYX-106), world-wide, excluding Greater China. Under the terms of the agreement, Biosion will receive a $10 million up-front license fee from Pyxis Oncology. In addition to the up-front payment, Biosion has the potential to receive significant milestone payments for PYX-106, totaling up to $222.5 million and  single to low double-digit royalties on commercial sales. Pyxis Oncology plans on submitting the IND for PYX-106 to the FDA by the second half of 2022 and initiating a Phase 1 trial shortly thereafter. Under the agreement, Pyxis Oncology has the opportunity to license additional preclinical assets that target anti-Siglec-15 using other approaches to treatment.

“The anti-Siglec 15 monoclonal antibody, PYX-106, is an exciting addition to the Pyxis Oncology pipeline,” said Jay Feingold, MD, PhD, chief medical officer of Pyxis Oncology.   “I believe this potential best-in-class program will address high unmet medical need in a variety of solid tumors including non-small cell lung cancer and head and neck cancer.  As an oncologist, my passion has been advancing potential breakthrough medicines to treat patients with difficult-to-treat cancers who have little hope in the advanced and progressive setting.”

Biosion continues to deliver breakthrough therapies to address unmet medical needs of patients worldwide. To accelerate the global development of its innovative pipeline, Biosion is expanding worldwide partnerships with leading biotech companies. “The licensing of our anti-Siglec-15 mAb to Pyxis Oncology for global development demonstrates the strength of our discovery engine to generate antibody-based therapeutics with superior properties” said Mingjiu Chen, Ph.D., chief executive officer and founder of Biosion. Dr. Chen continued “Data from anti-Siglec-15 preclinical studies show that BSI-060T has high affinity, high cell binding and activity, dose-proportional activity on reducing immunosuppression of Siglec-15 on T cells and long half-life that will allow BSI-060T to become a best-in-class mAb in the treatment of solid tumors.”

About Biosion, Inc.

Biosion is a global R&D biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived technologies including the H³ antibody discovery, SynTracer™ HT-endocytosis and Flexibody™ bispecific platforms. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in phase 1 clinical trials for atopic dermatitis and severe asthma. Biosion and partners have plans to progress additional assets into the clinic for oncology indications over the next year. Biosion has operations in the US, Australia, and China. To learn more about Biosion visit www.biosion.com.

About Pyxis Oncology, Inc. 

Pyxis Oncology, Inc. is a multi-asset, multi-modality company focused on defeating difficult to treat cancers and improving patient lives. By leveraging our fully integrated research, development and commercial capabilities, our expert team is efficiently building a diversified portfolio of next-generation therapeutics. Pyxis Oncology’s therapeutic candidates are designed to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis Oncology has developed a broad portfolio of novel antibody-drug conjugate product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. To learn more about Pyxis Oncology, visit www.pyxisoncology.com.

Biosion, Inc. Appoints Joel Edwards, MBA, as Chief Business Officer

Newark, DE, U.S. and Nanjing, China – February 21, 2022.  Biosion, Inc. (“Biosion”), a global clinical stage biotechnology company, today announced the appointment of Joel Edwards as chief business officer. In this position, he is responsible for strategic leadership over all aspects of the company’s global business development and alliance management activities. He will report to Dr. Mingjiu Chen, chief executive officer (CEO). Prior to joining Biosion, Mr. Edwards was most recently vice president of corporate strategy and operations at Ionis Pharmaceuticals.

“We are delighted to welcome Joel to our executive leadership team in this important role as we continue to expand global business development and alliances,” said Dr. Mingjiu Chen, founder, chairman and CEO of Biosion. “Joel’s deep understanding of the biotechnology business, coupled with his successful track record in corporate deal-making and alliance management, will be instrumental in driving Biosion’s next stage of global growth. We look forward to leveraging his experience as we continue to maximize the potential of our powerful drug discovery engine and further advance our innovative pipeline into the clinic.”  

“I look forward to working with the team to execute on Biosion’s vision to bring new breakthrough therapies to patients globally by forming strategic partnerships with industry leading biotech and pharmaceutical companies,” said Mr. Edwards. “Biosion has the tools and talent in place to rapidly grow its pipeline that includes innovative approaches to treat unmet needs. I’m excited to contribute to this important inflection point in the Biosion’s history and future growth as a premier in global for global biotech company.”

Mr. Edwards brings to Biosion nearly 25 years of broad pharmaceutical industry experience in business development, alliance management, and corporate development. During his 13 years at Ionis Pharmaceuticals, he was responsible for bringing in greater than $3.5B in partnership R&D revenue and led the M&A activities when Ionis purchased its subsidiary company. Mr. Edwards also managed collaborations while at Ionis and Valeant resulting in four marketing approvals and commercial launches with large pharma partners. Prior to Ionis, he worked in alliance and portfolio management roles while at Valeant Pharmaceuticals and Lexicon Pharmaceuticals. Mr. Edwards holds a M.B.A. from Colorado State University and a Bachelor of Science degree from Ball State University. 

Biosion, Inc. Appoints Anthony Yeh, Ph.D., as Chief Strategy Officer and Head of China BD

Newark, DE, U.S. and Nanjing, China – January 3, 2022.  Biosion, Inc. (“Biosion”), a global clinical stage biotechnology company, today announced the appointment of Dr. Anthony Yeh to the position of Chief Strategy Officer and Head of China business development (BD), where he will lead corporate strategy, China BD, and capital fundraising. He will report to Dr. Mingjiu Chen, Chief Executive Officer (CEO). Prior to joining Biosion, Dr. Yeh was most recently Vice President, Head of Corporate Strategy, Investor Relations and Capital Market at CStone Pharmaceuticals (HKSE:2616).

“We are pleased to welcome Anthony to Biosion as we continue to expand globally and strengthen our executive leadership,” said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion. “With the unique combination of cross-cultural background, outstanding scientific training, and extensive experience in the biopharma industry, Anthony represents the next generation of leaders who are the driving force for the globalization of China-based innovation. We look forward to his leadership as we advance toward our vision of delivering breakthrough biologics to patients worldwide.”

“Since I came back to China in 2007, China’s biopharmaceutical industry has undergone a momentus shift, from biosimilar-focused into one that nurtures innovation, and from domestic-focused into one that pivots towards globalization,” said Dr. Yeh. “Based on its global development capabilities, proprietary discovery platforms, and rich pipeline of innovative biologics, Biosion is becoming the front runner leading the next wave of China biopharmaceutical industry evolution. I look forward to joining Biosion’s world-class team to expand its global partnerships and accelerate global capital access.”

Dr. Yeh brings to Biosion over 15 years of experience in healthcare, investment, and management consulting. During his tenure at CStone Pharmaceuticals (HKSE: 2616), Dr. Yeh served several different leadership roles in helping to build CStone through public listing and eventually to commercialization stage. Prior to CStone, Dr. Yeh was Regional Head of Business Economics and Strategy at Abbott (NYSE: ABT) and engagement manager at L.E.K. Consulting where he specialized in life sciences strategy and M&A. Dr. Yeh holds a Ph.D. in Molecular Medicine from University of Oxford and a Bachelor of Science (honors) from Queensland University of Technology.

Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products

This license agreement continues to build on Biosion’s efforts to create and develop meaningful biologics to treat resistant, relapsed and residual disease for patients worldwide.

Newark, DE, USA, Nanjing, China – December 13, 2021.  Biosion, Inc. (“Biosion”), a global, clinical stage biotech company announced today that OBI Pharma Inc. (“OBI Pharma”) and Biosion have signed an exclusive license agreement providing OBI Pharma worldwide rights, excluding China to Biosion’s proprietary anti-Trop2 humanized monoclonal antibody, BSI04702. The license agreement enables OBI Pharma to conduct further preclinical and clinical development, registration, and commercialization of BSI04702 as an Antibody Drug Conjugate and other derivative products. Under the terms of the agreement, OBI Pharma will pay license fees to Biosion, including an upfront payment, future development milestones and net sales royalties.  The specific terms of the agreement were not disclosed.

“The licensing of our anti-TROP-2 mAb to OBI Pharma for global development further exhibits the strength of our Discovery engine and proprietary SynTracerTM HT-endocytosis platform to identify superior mAbs, ideal as ADCs” said Dr. Hugh Davis, Chief Operations Officer of Biosion, Inc. and President of Biosion USA.  “We are looking forward to partnering with OBI Pharma to advance BSI-04702 into the clinic and making a difference for patients worldwide.”

BSI04702 is an anti-TROP2 humanized monoclonal antibody with differentiated properties relative to existing mAbs that bind TROP-2.  It was created through Biosion’s proprietary Discovery engine and SynTracerTM HT-endocytosis Platform.

About Biosion, Inc.

For more information and full pipeline details, please visit www.biosion.com.

About OBI Pharma , Inc.

For more information and full pipeline details, please visit www.obipharma.com.

Media and Investor Contact:

Frank Liu, Ph.D.

Senior Director, Business Development

Biosion USA, Inc.

Phone: +1-302-998-5126

E-mail: Frank.Liu@Biosion.com

Biosion, Inc. Completed Pre-B+ Round Financing to Accelerate the Discovery and Global Development of Its Innovative Biologics Pipeline

New funding will strengthen Biosion’s “In Global For Global” positioning by accelerating its clinical pipeline and expanding its global biologics development teams

Newark, DE, Nanjing CN – Dec 9, 2021. Biosion Inc. (“Biosion”), a global, clinical-stage biotech company, today announced completion of a 200 million RMB preB+ financing round (including preB 2nd tranche financing) to accelerate discovery and global development of its innovative biologics portfolio targeting immunologic and cancer diseases. The financing was led by 3E Bioventures Capital, joined by Chase Capital. Concurrent with the financing, Mr. Lei Liu, the Director of 3E Bioventures Capital will join Biosion’s Board of Directors. Index Capital acts as the sole financial advisor for the current round of financing.

 “We are pleased to welcome 3E Bioventures Capital – a prestigious professional bio-venture capital firm – to join our effort in building our differentiated preclinical and clinical development portfolio, our global biologics development team and to further enable our strategy to be a leading “In Global For Global” biotech company” said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion.

Dr. Karen Liu, Partner of 3E Bioventures Capital, said: “We believe GLOBALIZATION is the big theme for the next generation of biopharma. The capability of accessing a global talent pool, leveraging territorial clinical resources, and navigating through regional regulatory barriers is key to translating novel science from concept to product. We are excited and confident that Biosion is on the launchpad to lead this wave of industry change with its world-class leadership team.”

Through recent significant enhancement of the Executive Leadership team, Advisory Board and Global Development team, Biosion is now poised to substantially accelerate global clinical development efforts of its innovative biologics pipeline.

About Biosion, Inc.

Biosion is a leading “In Global For Global” clinical stage biotechnology company developing innovative biologics to address resistant, relapsed and residual disease for patients worldwide. Established in 2017, Biosion has assembled a world-class team with extensive experience in global biologics development and built an oncology and auto-immune focused pipeline of innovative biologics through its internally-derived proprietary technologies, including the H3 hybridoma platform, SynAbTM synergistic antibody platform, SynTracerTM HT-endocytosis screening platform, and FlexibodyTM bispecific platform. Biosion’s mission is to discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftmanship for patients worldwide. Biosion is actively seeking global partners who are interested in licensing, partnership or co-development opportunities. For more information and full pipeline details, please visit www.biosion.com.

About 3E Bioventures Capital

3E Bioventures Capital is dedicated to investing in cutting-edge life sciences and biomedical technologies, with a focus on breakthrough first-in-class therapies and disruptive cross-disciplinary innovations in medical devices and diagnostics. 3E Bioventures takes on a science-driven, entrepreneur-friendly investment philosophy by working closely with companies and research institutions to develop drugs or products that have strong unmet medical needs. With offices in Beijing, Shanghai, and the San Francisco Bay Area, 3E Bioventures leverages its experience, capabilities, and network to help companies tap into markets and resources across the Pacific and advance with greater speed and capital efficiency. The motto of 3E Bioventures Capital is captured in its name 3E: Expertise, Efficiency, Execution.

About Chase Capital

Chase Capital is a professional investment institution focusing on early to mid-stage equity investment, with a core focus on two emerging industries, including biopharmaceutical and technology innovation. The funds managed by Chase Capital are mainly RMB funds and have invested in and incubated more than 20 domestic and foreign innovative companies, including HuiYu Pharmaceutical (688553), Harbour Biomed (02142) Elpiscience, Ab&b Bio-Tech, and other leading companies. With offices in Nanjing and Suzhou, Chase Capital focuses on the Yangtze River Delta region. Adhering to the concept of “focus on professionalism and accompany growth”, we hope to provide multi-faceted services for each partner company and help them grow into leading companies in the industry, as well as providing long-term development space and value recognition for investors and company partners.

Close Bitnami banner
Bitnami